Safety of HRX215 in Patients After Minor and Major Liver Resection

Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of HRX215 in Participants After Major Hepatectomy, Preceded by Two Open Pilot Parts in Participants After Minor and After Major Hepatectomy Due to Colon Carcinoma Metastases

The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases.

The objectives are:

1. to learn about the safety and tolerability of HRX215
2. to learn about how the body absorbs, distributes, and gets rid of HRX215.
3. to learn about clinical activity of HRX215

Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.

The study is designed to evaluate primarily the safety of HRX215, first after minor liver resection and subsequently in participants after major liver resection. Participants undergoing major liver resection will start treatment shortly before liver resection surgery and will receive 28 days of treatment with HRX215 or placebo twice daily with follow up visits at 3 and 6 months.

Participants will take HRX215 or a placebo twice a day for 28 days. Daily visits for the first 7 days of treatment for checkups and tests which may either be in the hospital or outpatient after 3 days. Clinic visits every two weeks for the next two visits. Additional clinic visits 3 months and 6 months after the start of treatment.

The pharmacokinetics will be compared with the results of the phase I studies in healthy subjects.

Secondary objectives will include evaluation of liver volume and liver volume increase postoperatively.

Inclusion Criteria:

• Participants with liver metastases originating from colon carcinoma planned for R0-intended hepatectomy for colorectal liver metastases
• Part 1 only: stable participants within 1-3 days after minor liver resection, normal non-tumor liver parenchyma
• Part 2 and 3 only: Major liver resection.
• Low estimated risk for post-hepatectomy liver failure PHLF

Further inclusion criteria apply

Exclusion Criteria:

• Liver Cirrhosis
• Preoperative presence of clinical ascites
• Any other hepatobiliary cancer
• BMI >35 kg/m2
• ASA Score >4
• Peritoneal carcinomatosis

Further exclusion criteria apply